Skip to main content
Erschienen in: Journal of Endocrinological Investigation 10/2014

01.10.2014 | Original Article

The impact of real practice inappropriateness and devices’ inefficiency to variability in growth hormone consumption

verfasst von: F. Spandonaro, M. Cappa, R. Castello, F. Chiarelli, E. Ghigo, L. Mancusi

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Growth hormone (GH) consumption is the object of a particular attention by regulatory bodies, due to its financial impact; nevertheless, GH treatment has been demonstrated to be cost-effective and is, therefore, usually reimbursed by public health service systems. In Italy, significant differences in GH consumption between regions have been recorded. Different appropriateness in real practice is a possible explanation, but the proportion of drug wasted due to different combinations of therapeutic regimes and types of devices used in drug administration is a complementary explanation. Aim of the study is, therefore, to determine how much of the variability in GH consumption is actually due to differences in clinical practice, and how much to waste.

Materials and methods

A model was settled to estimate the population with indication for GH administration, separately for children, transition subjects and adults, based on both the scientific evidence available and directly collected clinical evaluations. A systematic literature search was conducted using Cochrane Library (HTA and NHSEE) databases, Medline via Ovid, Econlit via Ovid, Embase.

Conclusion

The model applied to the Italian population showed that there was apparently unexplainable over-prescription and potential under-prescription in various regions, ranging from 20 to 40 % less than the estimated theoretical consumption to over 200 %. Wastage, at level of single device, could amount to as much as 15 % of the consumption, demonstrating that price per mg is not in general a good proxy of the cost per mg of therapy. Our estimates of the wastage shows a significant potential gap in the model assessment of the HTA bodies, as far as they do not explicitly take into account the issue of wastage and, consequently, the actual variability in local clinical practice.
Fußnoten
1
SHOX has not been included in following analysis because till 2011, in Italy, GH wasn’t authorized for the specific indication.
 
2
Adult onset: patients who have growth hormone deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; childhood onset: patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.
 
3
It’s worth noting that since 2006 a biosimilar GH formulation is available (EMEA/H/C/000607).
 
4
To date, devices available differ in technical aspects (for example, they may or not have a needle) and in capacity; the amount of device-related waste is consequent to the actual “divisibility” of the capacity to the dosage, as well as to the possibility of using all the GH before it expires. No other potential sources of inefficiency, as malfunctioning, have been considered. More details in [10].
 
5
In Italy public reimbursement rely on the predisposition of a therapeutic plan by Regional specialized centres.
 
Literatur
1.
Zurück zum Zitat Review of NICE (2010) Human growth hormone (somatropin) for the treatment of growth failure in children NICE technology appraisal guidance, p. 188 Review of NICE (2010) Human growth hormone (somatropin) for the treatment of growth failure in children NICE technology appraisal guidance, p. 188
2.
Zurück zum Zitat Growth Hormone Research Society (2000) Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 85:3990–3993 Growth Hormone Research Society (2000) Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 85:3990–3993
3.
Zurück zum Zitat Cook DM, Yuen KC, Biller BM et al (2009) Medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients. Endocr Pract 15 (Suppl 2) Cook DM, Yuen KC, Biller BM et al (2009) Medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients. Endocr Pract 15 (Suppl 2)
4.
Zurück zum Zitat Growth Hormone Research Society (1998) Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency. Summary statement of the Growth Hormone Research Society Workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 83:379–381 Growth Hormone Research Society (1998) Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency. Summary statement of the Growth Hormone Research Society Workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 83:379–381
5.
Zurück zum Zitat Li H, Banerjee S, Dunfield L et al (2007) Recombinant human growth hormone for treatment of Turner syndrome: systematic review and economic evaluation [Technology report number 96]. Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa Li H, Banerjee S, Dunfield L et al (2007) Recombinant human growth hormone for treatment of Turner syndrome: systematic review and economic evaluation [Technology report number 96]. Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa
7.
Zurück zum Zitat d’Andon A, Barré S, Hamers F et al (2011) L’hormone de la croissance chez l’enfant non déficitaire. In: Evaluation du service rendu à la collectivité. HAS/Service Evaluation des Médicaments et Service Evaluation Economique et Santé Publique d’Andon A, Barré S, Hamers F et al (2011) L’hormone de la croissance chez l’enfant non déficitaire. In: Evaluation du service rendu à la collectivité. HAS/Service Evaluation des Médicaments et Service Evaluation Economique et Santé Publique
8.
9.
Zurück zum Zitat Atti a cura di Pricci F, Agazio E. III Convegno Il Treatment con l’ormone somatotropo in Italia; Rapporti ISTISAN 12/24, Istituto Superiore di Sanità 2011, ISSN 1123-3117 Atti a cura di Pricci F, Agazio E. III Convegno Il Treatment con l’ormone somatotropo in Italia; Rapporti ISTISAN 12/24, Istituto Superiore di Sanità 2011, ISSN 1123-3117
10.
Zurück zum Zitat Spandonaro F, Mancusi L (2013) Evidenze di efficacia, efficienza e impatto organizzativo per le terapie della GHD. Farmeconomia. Health Economics and Therapeutic Pathways 14(1):7–17 Spandonaro F, Mancusi L (2013) Evidenze di efficacia, efficienza e impatto organizzativo per le terapie della GHD. Farmeconomia. Health Economics and Therapeutic Pathways 14(1):7–17
11.
Zurück zum Zitat Takeda A, Cooper K, Bird A et al (2010) Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess 14:1–209, iii–iv. http://dx.doi.org/10.3310/hta14420 Takeda A, Cooper K, Bird A et al (2010) Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess 14:1–209, iii–iv. http://​dx.​doi.​org/​10.​3310/​hta14420
12.
13.
Zurück zum Zitat Lindgren AC, Ritzén EM (1999) Five years of growth hormone treatment in children with Prader–Willi syndrome. Acta Paediatr Suppl 88(433):109–111PubMedCrossRef Lindgren AC, Ritzén EM (1999) Five years of growth hormone treatment in children with Prader–Willi syndrome. Acta Paediatr Suppl 88(433):109–111PubMedCrossRef
14.
Zurück zum Zitat Butler MG (1990) Prader–Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet 35(3):319–332PubMedCrossRef Butler MG (1990) Prader–Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet 35(3):319–332PubMedCrossRef
15.
Zurück zum Zitat Molinas C, Cazals L, Diene G et al (2008) French database of children and adolescents with Prader–Willi syndrome. BMC Med Genet 9(89). doi:10.1186/1471-2350-9-89 Molinas C, Cazals L, Diene G et al (2008) French database of children and adolescents with Prader–Willi syndrome. BMC Med Genet 9(89). doi:10.​1186/​1471-2350-9-89
16.
Zurück zum Zitat Karlberg J, Albertsson-Wikland K (1995) Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res 38(5):733–739PubMedCrossRef Karlberg J, Albertsson-Wikland K (1995) Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res 38(5):733–739PubMedCrossRef
17.
Zurück zum Zitat Albertsson-Wikland K, Wennergren G, Wennergren M et al (1993) Longitudinal follow-up of growth in children born small for gestational age. Acta Paediatr 82(5):438–443PubMedCrossRef Albertsson-Wikland K, Wennergren G, Wennergren M et al (1993) Longitudinal follow-up of growth in children born small for gestational age. Acta Paediatr 82(5):438–443PubMedCrossRef
18.
Zurück zum Zitat Ardissino G, Daccò V, Testa S et al (2003) Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 111(4 Pt 1):382–387CrossRef Ardissino G, Daccò V, Testa S et al (2003) Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 111(4 Pt 1):382–387CrossRef
19.
Zurück zum Zitat Migliaretti G, Aimaretti G, Borraccino A et al (2006) Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002–2004: data from the GH Registry. J Endocrinol Invest 29(5):438–442PubMedCrossRef Migliaretti G, Aimaretti G, Borraccino A et al (2006) Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002–2004: data from the GH Registry. J Endocrinol Invest 29(5):438–442PubMedCrossRef
20.
Zurück zum Zitat Cacciari E, Milani S, Balsamo A et al (2006) Italian cross-sectional growth charts for height, weight and BMI (2 to 29 yr). J Endocrinol Invest 29:581–593PubMedCrossRef Cacciari E, Milani S, Balsamo A et al (2006) Italian cross-sectional growth charts for height, weight and BMI (2 to 29 yr). J Endocrinol Invest 29:581–593PubMedCrossRef
21.
Zurück zum Zitat Bonfig W, Bechtold S, Bachmann S et al (2008) Reassessment of the optimal growth hormone cut-off level in insulin tolerance testing for growth hormone secretion in patients with childhood-onset growth hormone deficiency during transition to adulthood. J Pediatr Endocrinol Metab 21:1049–1056PubMedCrossRef Bonfig W, Bechtold S, Bachmann S et al (2008) Reassessment of the optimal growth hormone cut-off level in insulin tolerance testing for growth hormone secretion in patients with childhood-onset growth hormone deficiency during transition to adulthood. J Pediatr Endocrinol Metab 21:1049–1056PubMedCrossRef
23.
Zurück zum Zitat Regione Veneto, unpublished data from the Veneto Regional Commission for the prescription of growth hormone Regione Veneto, unpublished data from the Veneto Regional Commission for the prescription of growth hormone
Metadaten
Titel
The impact of real practice inappropriateness and devices’ inefficiency to variability in growth hormone consumption
verfasst von
F. Spandonaro
M. Cappa
R. Castello
F. Chiarelli
E. Ghigo
L. Mancusi
Publikationsdatum
01.10.2014
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 10/2014
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-014-0138-x

Weitere Artikel der Ausgabe 10/2014

Journal of Endocrinological Investigation 10/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.